HOLLISTER, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2024.
“Our year-on-year double-digit revenue growth in the third quarter gives us confidence that we have put Teknova on track for long-term success,” said Stephen Gunstream, President and Chief Executive Officer at Teknova. “We believe the difficult decisions we made to reduce expenses and raise modest amounts of capital, while retaining our core strategy, are now beginning to bear fruit. We remain confident that we’ll finish the back half of 2024 with double-digit revenue growth and look to build on this momentum as we enter 2025.”
“During the third quarter of 2024, we continued to deliver improved results on several key metrics over the second quarter of 2024, as we again managed our operating expenses and capital expenditures to plan. We typically see revenue soften in the fourth quarter, primarily due to fewer business days, and are thus maintaining our full-year outlook of $35-38 million of revenue while lowering our free cash outflow outlook from less than $18 million to less than $16 million,” explained Matt Lowell, Teknova’s Chief Financial Officer.
Corporate and Financial Updates
Revenue for the Third Quarter and Year-to-Date
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| (Dollars in thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Lab Essentials | $ | 7,161 | $ | 7,274 | $ | 22,065 | $ | 22,112 | ||||||||
| Clinical Solutions | 1,964 | 597 | 5,247 | 5,859 | ||||||||||||
| Other | 451 | 298 | 1,168 | 846 | ||||||||||||
| Total revenue | $ | 9,576 | $ | 8,169 | $ | 28,480 | $ | 28,817 | ||||||||
Third Quarter 2024 Financial Results
Total revenue for the third quarter 2024 was $9.6 million, up 17% compared to $8.2 million in the third quarter 2023. Lab Essentials revenue was $7.2 million in the third quarter 2024, largely unchanged from $7.3 million in the third quarter 2023. Clinical Solutions revenue was $2.0 million in the third quarter 2024, up 229% compared to $0.6 million in the third quarter 2023.
Gross profit for the third quarter 2024 was $0.1 million, compared to $1.5 million in the third quarter 2023. Gross margin for the third quarter 2024 was 0.9%, compared to 18.0% in the third quarter 2023. The decrease in gross profit percentage was attributable to a $2.8 million in non-recurring, non-cash charges related to the disposal of expired inventory and write down of excess inventory created in the second half of 2022 when we increased production in anticipation of persistent high demand. Excluding this $2.8 million charge, gross margin would have been 29.8% in the third quarter 2024, resulting in an increase in the gross profit percentage primarily driven by higher Clinical Solutions revenue coupled with reduced headcount.
Operating expenses for the third quarter 2024 were $7.5 million, compared to $10.2 million in the third quarter 2023. Excluding the non-recurring charges of $0.4 million recorded in the third quarter of 2023 and related to the write-off of at-the-market facility costs, operating expenses were down $2.3 million. The decrease was driven primarily by reduced headcount and spending, in particular on professional fees.
Net loss for the third quarter 2024 was $7.6 million, or negative $0.15 per diluted share, compared to $10.2 million, or negative $0.34 per diluted share, for the third quarter 2023.
Adjusted EBITDA for the third quarter 2024 was negative $5.0 million, compared to negative $5.5 million for the third quarter 2023. Excluding the $2.8 million charge, Adjusted EBITDA would have been negative $2.2 million. Free Cash Flow was negative $2.4 million for the third quarter 2024, compared to negative $5.4 million for the third quarter 2023. A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.
Reiterates 2024 Outlook
Teknova is reiterating its fiscal 2024 outlook for revenue while lowering its anticipated free cash outflow. The Company continues to anticipate total revenue of $35 million to $38 million for the fiscal year ending December 31, 2024 (“2024”), which now assumes roughly 2% growth in Lab Essentials. The Company lowers anticipated free cash outflow from less than $18 million to less than $16 million for 2024.
Upcoming Investor Conference Attendance
Stephens Annual Investment Conference (Nashville, TN)
Wednesday, November 20, 2024
Conference Call and Webcast
Teknova will host a webcast and conference call on Thursday, November 7, 2024, beginning at 5:30 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers, reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.
Non-GAAP Financial Measures
This press release contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of its business and the effectiveness of its business strategies: (a) Adjusted EBITDA and (b) Free Cash Flow.
Teknova defines Adjusted EBITDA as net loss adjusted for interest income (expense), net, provision for (benefit from) income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that Teknova does not consider representative of its ongoing operating performance.
Teknova defines Free Cash Flow as cash used in operating activities plus purchases of property, plant, and equipment.
Teknova provides Adjusted EBITDA and Free Cash Flow in this press release because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in Teknova’s industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in Teknova’s operating results because they exclude items that are not indicative of Teknova’s core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies.
A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.
Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to Teknova’s anticipated total revenue, including our expectations for 2024 revenue and free cash outflow guidance, expected growth in Lab Essentials and Clinical Solutions, and other statements about Teknova’s business prospects, including about the Company’s profitability, strategy of managing operating expenses, and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond Teknova’s control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, demand for Teknova’s products (including the potential delay to or pausing of customer orders); Teknova’s assessment of fundamental indicators of future demand across its target customer base; Teknova’s cash flows and revenue growth rate; Teknova’s supply chain, sourcing, manufacturing, and warehousing; inventory management; risks related to global economic and marketplace uncertainties, including those related to the conflicts in Ukraine and the Middle East; reliance on a limited number of customers for a high percentage of Teknova’s revenue; potential acquisitions and integration of other companies; and other factors discussed in the “Risk Factors” section of Teknova’s most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in Teknova’s Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although Teknova believes that the expectations reflected in its forward-looking statements are reasonable, Teknova does not know whether its expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by Teknova on its website or otherwise. Teknova does not undertake any obligation to update, amend, or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
Investor Contact
Matt Lowell
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 831-637-1100
Media Contact
Jennifer Henry
Senior Vice President, Marketing
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 831-313-1259
| ALPHA TEKNOVA, INC. Condensed Statements of Operations (Unaudited) (In thousands, except share and per share data) | ||||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenue | $ | 9,576 | $ | 8,169 | $ | 28,480 | $ | 28,817 | ||||||||
| Cost of sales | 9,486 | 6,697 | 23,377 | 19,856 | ||||||||||||
| Gross profit | 90 | 1,472 | 5,103 | 8,961 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 627 | 1,397 | 2,165 | 4,256 | ||||||||||||
| Sales and marketing | 1,640 | 2,412 | 4,763 | 6,929 | ||||||||||||
| General and administrative | 4,968 | 6,138 | 17,832 | 19,426 | ||||||||||||
| Amortization of intangible assets | 287 | 287 | 861 | 860 | ||||||||||||
| Long-lived assets impairment | — | — | — | 2,195 | ||||||||||||
| Total operating expenses | 7,522 | 10,234 | 25,621 | 33,666 | ||||||||||||
| Loss from operations | (7,432 | ) | (8,762 | ) | (20,518 | ) | (24,705 | ) | ||||||||
| Other expenses, net | ||||||||||||||||
| Interest expense, net | (141 | ) | (791 | ) | (558 | ) | (1,006 | ) | ||||||||
| Loss on extinguishment of debt | — | (824 | ) | — | (824 | ) | ||||||||||
| Other income, net | — | 233 | — | 417 | ||||||||||||
| Total other expenses, net | (141 | ) | (1,382 | ) | (558 | ) | (1,413 | ) | ||||||||
| Loss before income taxes | (7,573 | ) | (10,144 | ) | (21,076 | ) | (26,118 | ) | ||||||||
| (Benefit from) provision for income taxes | (8 | ) | 9 | (50 | ) | 6 | ||||||||||
| Net loss | $ | (7,565 | ) | $ | (10,153 | ) | $ | (21,026 | ) | $ | (26,124 | ) | ||||
| Net loss per share—basic and diluted | $ | (0.15 | ) | $ | (0.34 | ) | $ | (0.47 | ) | $ | (0.91 | ) | ||||
| Weighted average shares used in computing net loss per share—basic and diluted | 51,821,395 | 29,956,930 | 44,520,132 | 28,810,068 | ||||||||||||
| ALPHA TEKNOVA, INC. Condensed Balance Sheets (Unaudited) (In thousands) | ||||||||
| As of September 30, | As of December 31, | |||||||
| 2024 | 2023 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 6,145 | $ | 28,484 | ||||
| Short-term investments, held -to-maturity | 25,546 | — | ||||||
| Accounts receivable, net | 4,605 | 3,948 | ||||||
| Inventories, net | 7,674 | 11,594 | ||||||
| Prepaid expenses and other current assets | 1,960 | 1,634 | ||||||
| Total current assets | 45,930 | 45,660 | ||||||
| Property, plant, and equipment, net | 46,715 | 50,364 | ||||||
| Operating right-of-use lease assets | 16,558 | 16,472 | ||||||
| Intangible assets, net | 13,378 | 14,239 | ||||||
| Other non-current assets | 1,518 | 1,852 | ||||||
| Total assets | $ | 124,099 | $ | 128,587 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 975 | $ | 1,493 | ||||
| Accrued liabilities | 4,373 | 5,579 | ||||||
| Current portion of operating lease liabilities | 1,843 | 1,803 | ||||||
| Current portion of long-term debt | 2,528 | — | ||||||
| Total current liabilities | 9,719 | 8,875 | ||||||
| Deferred tax liabilities | 867 | 919 | ||||||
| Other accrued liabilities | 30 | 102 | ||||||
| Long-term debt, net | 10,857 | 13,251 | ||||||
| Long-term operating lease liabilities | 15,358 | 15,404 | ||||||
| Total liabilities | 36,831 | 38,551 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | 1 | — | ||||||
| Additional paid-in capital | 200,079 | 181,822 | ||||||
| Accumulated deficit | (112,812 | ) | (91,786 | ) | ||||
| Total stockholders’ equity | 87,268 | 90,036 | ||||||
| Total liabilities and stockholders’ equity | $ | 124,099 | $ | 128,587 | ||||
| ALPHA TEKNOVA, INC. Condensed Statements of Cash Flows (Unaudited) (In thousands) | ||||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Operating activities: | ||||||||||||||||
| Net loss | $ | (7,565 | ) | $ | (10,153 | ) | $ | (21,026 | ) | $ | (26,124 | ) | ||||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||||||||
| Bad debt expense | 5 | 13 | 61 | 21 | ||||||||||||
| Inventory reserve | 3,339 | 97 | 4,235 | 130 | ||||||||||||
| Depreciation and amortization | 1,671 | 1,622 | 4,933 | 4,049 | ||||||||||||
| Stock-based compensation | 760 | 1,035 | 2,900 | 3,115 | ||||||||||||
| Deferred taxes | (8 | ) | 9 | (52 | ) | 5 | ||||||||||
| Accrued interest income on short-term investments | (118 | ) | — | (118 | ) | — | ||||||||||
| Amortization of debt financing costs | 103 | 205 | 291 | 415 | ||||||||||||
| Non-cash lease expense | 46 | 55 | 140 | 86 | ||||||||||||
| Loss on disposal of property, plant, and equipment | — | 5 | 49 | 5 | ||||||||||||
| Long-lived assets impairment | — | — | — | 2,195 | ||||||||||||
| Loss on extinguishment of debt | — | 824 | — | 824 | ||||||||||||
| Changes in operating assets and liabilities: | ||||||||||||||||
| Accounts receivable | (13 | ) | (402 | ) | (718 | ) | (721 | ) | ||||||||
| Contract assets | — | 1,050 | — | — | ||||||||||||
| Inventories | (26 | ) | 453 | (315 | ) | 649 | ||||||||||
| Income taxes receivable | — | 22 | — | 22 | ||||||||||||
| Prepaid expenses and other current assets | (1,356 | ) | (1,736 | ) | (943 | ) | (694 | ) | ||||||||
| Other non-current assets | 128 | 78 | 334 | 300 | ||||||||||||
| Accounts payable | (41 | ) | 414 | (430 | ) | (948 | ) | |||||||||
| Accrued liabilities | 1,040 | 2,049 | (724 | ) | 815 | |||||||||||
| Other | (24 | ) | (22 | ) | (72 | ) | (66 | ) | ||||||||
| Cash used in operating activities | (2,059 | ) | (4,382 | ) | (11,455 | ) | (15,922 | ) | ||||||||
| Investing activities: | ||||||||||||||||
| Purchases of short-term investments | (25,428 | ) | — | (25,428 | ) | — | ||||||||||
| Proceeds from sale of property, plant, and equipment | — | — | 125 | — | ||||||||||||
| Purchases of property, plant, and equipment | (331 | ) | (972 | ) | (558 | ) | (7,622 | ) | ||||||||
| Cash used in investing activities | (25,759 | ) | (972 | ) | (25,861 | ) | (7,622 | ) | ||||||||
| Financing activities: | ||||||||||||||||
| Proceeds from equity financing, net | 15,141 | 22,915 | 15,104 | 22,915 | ||||||||||||
| Repayment of long-term debt | — | (10,000 | ) | — | (10,000 | ) | ||||||||||
| Proceeds from financed insurance premiums | 385 | 1,004 | 385 | 1,004 | ||||||||||||
| Repayment of financed insurance premiums | (163 | ) | (294 | ) | (572 | ) | (294 | ) | ||||||||
| Payment of debt issuance costs | — | — | (25 | ) | (24 | ) | ||||||||||
| Payment of at-the-market facility costs | — | — | — | (395 | ) | |||||||||||
| Proceeds from exercise of stock options | 4 | — | 4 | 76 | ||||||||||||
| Proceeds from issuance of common stock under employee stock purchase plan | — | — | 81 | 138 | ||||||||||||
| Cash used in financing activities | 15,367 | 13,625 | 14,977 | 13,420 | ||||||||||||
| Change in cash, cash equivalents, and restricted cash | (12,451 | ) | 8,271 | (22,339 | ) | (10,124 | ) | |||||||||
| Cash, cash equivalents, and restricted cash at beginning of period | 18,596 | 23,841 | 28,484 | 42,236 | ||||||||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | 6,145 | $ | 32,112 | $ | 6,145 | $ | 32,112 | ||||||||
| ALPHA TEKNOVA, INC. Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures (Unaudited) (In thousands) | ||||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Net loss – as reported | $ | (7,565 | ) | $ | (10,153 | ) | $ | (21,026 | ) | $ | (26,124 | ) | ||||
| Add back: | ||||||||||||||||
| Interest expense, net | (141 | ) | (791 | ) | (558 | ) | (1,006 | ) | ||||||||
| (Benefit from) provision for income taxes | (8 | ) | 9 | (50 | ) | 6 | ||||||||||
| Depreciation expense | 1,384 | 1,335 | 4,072 | 3,189 | ||||||||||||
| Amortization of intangible assets | 287 | 287 | 861 | 860 | ||||||||||||
| EBITDA | $ | (5,761 | ) | $ | (7,731 | ) | $ | (15,585 | ) | $ | (21,063 | ) | ||||
| Other and non-recurring expenses: | ||||||||||||||||
| Stock-based compensation expense | 760 | 1,035 | 2,900 | 3,115 | ||||||||||||
| Severance pay and other termination benefits | — | — | 1,287 | 725 | ||||||||||||
| Long-lived assets impairment | — | — | — | 2,195 | ||||||||||||
| Loss on extinguishment of debt | — | 824 | — | 824 | ||||||||||||
| Write-off of at-the-market facility costs | — | 395 | — | 395 | ||||||||||||
| Loss contingency | — | — | 73 | — | ||||||||||||
| Adjusted EBITDA | $ | (5,001 | ) | $ | (5,477 | ) | $ | (11,325 | ) | $ | (13,809 | ) | ||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Cash used in operating activities | $ | (2,059 | ) | $ | (4,382 | ) | $ | (11,455 | ) | $ | (15,922 | ) | ||||
| Purchases of property, plant, and equipment | (331 | ) | (972 | ) | (558 | ) | (7,622 | ) | ||||||||
| Free Cash Flow | $ | (2,390 | ) | $ | (5,354 | ) | $ | (12,013 | ) | $ | (23,544 | ) | ||||
This press release was published by a CLEAR® Verified individual.
| Last Trade: | US$8.55 |
| Daily Change: | 0.87 11.33 |
| Daily Volume: | 624,566 |
| Market Cap: | US$455.800M |
August 13, 2024 July 12, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
